Navigation Links
Confirmation of nitisinone efficacy for life-threatening liver disease
Date:10/31/2012

This release is available in French.

A consortium of Quebec researchers coordinated by the Medical Genetics Service of the Sainte-Justine UHC has just published the findings of a 25-year study on the treatment of tyrosinemia, a life-threatening liver disease of genetic origin, which is screened at birth in the province of Quebec, where it is much more frequent than anywhere else in the world. "After five years of treatment, no trace of the disease can be detected in the liver of newborns who were treated with nitisinone starting from the first month of life," states Dr. Grant Mitchell of the Sainte-Justine UHC and the University of Montreal, who is the senior author of a study published in Molecular Genetics and Metabolism in September 2012.

Due to a genetic mutation, tyrosine, an amino acid found in the diet, is not properly metabolized in the liver of children with tyrosinemia. Toxic compounds can therefore build up in the liver and trigger various complications such as liver cirrhosis and liver cancer, which most often require a liver transplant to ensure patient survival. The drug nitisinone produces spectacular results, since it lowers the level of toxins by modifying the way tyrosine is metabolized. If treatment is undertaken in the first month of a child's life and complied to, impaired liver function becomes normal again.

Forty years ago, 90 % of children with tyrosinemia died before ever reaching the age of two. The study shows that today, they can enjoy normal health for at least 18 years and possibly even for the rest of their lives. In Quebec, screening at birth has been performed since 1970 and nitisinone treatment has been available since 1994. The situation is different elsewhere in the world, where in most countries neonatal screening for tyrosinemia is not available.

In fact, outside Quebec, children are diagnosed with tyrosinemia only when they show up at the hospital with severe complications, usually when they are already a few months old. For these children, the study's findings are critical. "The treatment also helps children with a late diagnosis, because it prevents acute complications, notably the need for a liver transplant," explains Dr. Mitchell.

The Quebec group's findings erase all doubt about the efficacy of nitisinone treatment and the benefits of early tyrosinemia screening. The researchers hope that their conclusions will be quickly exported and adopted so children elsewhere in the world can also benefit from this rapid and optimal treatment.

Around the world, one person in 100,000 is afflicted with tyrosinemia. In Quebec, a genetic founder effect pushes this proportion up to one person in 16,000 and even one in 1,846 in the Saguenay region. According to Dr. Guy Parizeault, the pediatrician at the Chicoutimi Health and Social Service Center (CSSS) who took over from the study's first author, Dr. Jean Larochelle, as the physician in charge of local monitoring of children with tyrosinemia, "Quebec was the ideal place to conduct this research on tyrosinemia, since there were enough patients to draw valid scientific conclusions and the province enjoys close collaboration with the physicians in charge of monitoring and the group of parents of the affected children."

Study Details

To evaluate the efficacy of nitisinone, the researchers performed a retrospective examination of the course of the disease in patients in Quebec who had not received the treatment before 1994. They then compared their observations with the results of a prospective study of the course of the disease in patients who had been screened at birth starting in 1994. All of these patients were treated with nitisinone. Physicians from all of the university centers responsible for monitoring children with tyrosinemia in Quebec took part in the collaborative study. The children were monitored locally for their dietary and medical treatment and evaluated once a year at the Sainte-Justine UHC by a multidisciplinary team of medical specialists in genetics, liver diseases and medical imaging. The study was conducted in collaboration with patients who were members of a Quebec support group for children with tyrosinemia and their parents.

Despite the exciting conclusions, the researchers remain cautious. They stress the importance of continuing to monitor the development of complications related to tyrosinemia or the treatment itself. "We conducted this study over 25 years. It is long enough to be sure that nitisinone treatment definitely stops this liver disease or at least drastically slows down its progression," continues Dr. Mitchell. "This goes to show how some genetic diseases, even the most severe ones, are treatable," he concludes.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related medicine news :

1. UGA researchers boost efficacy of drugs by using nanoparticles to target powerhouse of cells
2. RV144 vaccine efficacy increased against certain HIV viruses
3. Are there gender differences in anti-HIV drug efficacy?
4. New research confirms efficacy of transcranial magnetic stimulation for depression
5. Published clinical trial demonstrates efficacy of Sea-Band for migraine-related nausea
6. Efficacy of herbal remedies for managing insomnia
7. New delivery method improves efficacy of 2 common Parkinsons disease medications
8. Atrial fibrillation: Flec-SL trial proves efficacy of short-term antiarrhythmic drug treatment
9. Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
10. Research shows efficacy of treatment model developed at Women & Infants
11. Legacy bead program helps children and their families cope with life-threatening illnesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... with so many different solutions on the market, it is easy to start ... Texas Premier Locksmith offers a complimentary security consultation. , Home Security Hardware ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading ... spend management, today announced that Keppel Corporation has selected Apptricity Travel and Expense ... , “We are excited to announce the partnership between Keppel and Apptricity for ...
(Date:2/21/2017)... Okla. (PRWEB) , ... February 21, 2017 , ... ... new Choctaw Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , ... by clinic tours for community members, clinic employees, the construction team and tribal ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... Doctors ... , CA, directed by Dr. Kendell Mendonca , to its growing network of ... compensation injuries including injuries stemming from car accidents such as whiplash, back pain, neck ...
(Date:2/21/2017)... Fort Worth, TX (PRWEB) , ... February 21, 2017 , ... ... planning assistance to communities in and around Tarrant County, is embarking on a six ... to research cures and treatments for cancer. , Cancer is one of the deadliest ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... SEATTLE , Feb. 22, 2017 ... translational development of novel immune modulating therapies, today ... the a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust ... preclinical pain models. The study also establishes the ... the treatment of chronic pain. The findings were ...
(Date:2/22/2017)... , Feb. 22, 2017  Soligenix, Inc. ... Company), a late-stage biopharmaceutical company focused on developing ... there is an unmet medical need, announced today ... been granted a European patent for the treatment ... and methods of treatment of skin conditions, complements ...
(Date:2/21/2017)... -- IBM (NYSE: IBM ) Research has today announced new ... the eye,s retina. The Melbourne based ... recognize abnormalities in retina images, which could in the future ... of patients who may be at risk of eye diseases ... the developed world. The research began in ...
Breaking Medicine Technology: